Abstract

  COVID-19, the global threat to the humanity, shares etiological cofactors with multiple diseases including Alzheimer’s disease (AD). Understanding the common links between COVID-19 and AD would harness strategizing therapeutic approaches against both. Considering the urgency of formulating COVID-19 medication, its AD association and manifestations have been reviewed here, putting emphasis on memory and learning disruption. COVID-19 and AD share common links with respect to angiotensin-converting enzyme 2 (ACE2) receptors, proinflammatory markers such as interleukin-1 (IL-1), IL-6, cytoskeleton-associated protein 4 (CKAP4), galactein-9 and APOE4 allele. Common etiological factors and common manifestations described in this review would aid in developing therapeutic strategies for both COVID-19 and AD and thus impact on eradicating the ongoing global threat. Thus, people suffering from COVID-19 or who have come round of it as well as people at risk of developing AD or already suffering from AD, would be benefitted.

Keywords: ACE2; ApoE4; Gal-9; Inflammation; Neuroinvasive

References

1. Desforges M., et al. “Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?” Viruses1 (2019): 14.
2. Asadi-Pooya AA and Simani L. “Central nervous system manifestations of COVID-19: a systematic review”. Journal of the Neurological Sciences 413 (2020): 116832.
3. Mao L., et al. “Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China”. JAMA Neurology 6 (2020): 1-9.
4. Fotuhi M., et al. “Neurobiology of COVID-19”. Journal of Alzheimer's Disease 1 (2020): 3-19.
5. Hardy JA and Higgins GA. “Alzheimer’s disease: the amyloid cascade hypothesis”. Science5054 (1992): 184.
6. Baig AM., et al. “Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms”. ACS Chemical Neuroscience 7 (2020): 995-998.
7. Li YC., et al. “The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients”. Journal of Medical Virology 6 (2020): 552-555.
8. Wrapp D., et al. “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation”. Science 6483 (2020): 1260-1263.
9. Bridwell R., et al. “Neurologic complications of COVID-19”. American Journal of Emergency Medicine 7 (2020): 1549-1549.
10. Sheraton M., et al. “A review of neurological complications of COVID-19”. Cureus 5 (2020): e8192.
11. Steardo L., et al. “Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19”. Acta Physiologica 3 (2020): e13473.
12. Wu Y., et al. “Nervous system involvement after infection with COVID-19 and other coronaviruses”. Brain, Behavior, and Immunity 87 (2020): 18-22.
13. Kabbani N and Olds JL. “Does COVID19 infect the brain? if so, smokers might be at a higher risk”. Molecular Pharmacology5 (2020): 351-353.
14. Whittaker A., et al. “Neurological Manifestations of COVID-19: a systematic review and current update”. Acta Neurologica Scandinavica 1 (2020): 14-22.
15. Hartung H and Aktas O. “COVID-19 and management of neuroimmunological disorders”. Nature Reviews Neurology 16 (2020): 347-348.
16. Varatharaj A., et al. “Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study”. The Lancet Psychiatry (2020).
17. Lahiri D and Ardila A. “COVID-19 pandemic: a neurological perspective”. Cureus4 (2020): e7889.
18. Cojocaru IM., et al. “Study of interleukin-6 production in Alzheimer's disease”. Romanian Journal of Internal Medicine 1 (2011): 55-58.
19. Motta M., et al. “Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression”. Immunology Letters 1 (2007): 46-51.
20. Bialuk I., et al. “IL-6 deficiency alters spatial memory in 4- and 24-month-old mice”. Neurobiology of Learning and Memory 155 (2018): 21-29.
21. Chen X., et al. “Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients”. Clinical Infectious Diseases (2020): ciaa 449.
22. Wang H., et al. “Multiple enzyme release, inflammation storm and hypercoagulability are prominent indicators for disease progression in COVID-19: a multi-centered, correlation study with CT imaging score (2020).
23. Ulhaq Z S and Soraya GV. “Interleukin-6 as a potential biomarker of COVID-19 progression”. Medecine et Maladies Infectieuses4 (2020): 382-383.
24. Patel H., et al. “Proteomic blood profiling in mild, severe and critical COVID-19 patients”. Med Rxiv (2020).
25. Zhang C., et al. “The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality”. The International Journal of Antimicrobial Agents 5 (2020): 105954.
26. Hüll M., et al. “Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options”. Neurobiology of Aging 5 (1996): 795-800.
27. Raphaël C., et al. “Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19”. Proceedings of the National Academy of Sciences of the United States of America32 (2020): 18951-18953.
28. Giulio C., et al. “”. Lancet Rheumatology 2 (2020): e325-e331.
29. Griffin WS., et al. “Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease”. Proceedings of the National Academy of Sciences of the United States of America 19 (1989): 7611-7615.
30. Pugh RC., et al. “The immune system and memory consolidation: a role for the cytokine IL-1beta”. Neuroscience and Biobehavioral Reviews 1 (2001): 29-41.
31. Sheng JG., et al. “In vivo and In vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis”. Neurobiology of Aging5 (1996): 761-766.
32. Depino AM., et al. “Learning modulation by endogenous hippocampal IL-1: blockade of endogenous IL-1 facilitates memory formation”. Hippocampus4 (2004): 526-535.
33. Lu X., et al. “Galectin-9 ameliorates respiratory syncytial virus-induced pulmonary immunopathology through regulating the balance between Th17 and regulatory T cells”. Virus Research 195 (2015): 162-171.
34. Caniglia JL., et al. “A potential role for galectin-3 inhibitors in the treatment of COVID-19”. Peer Journal 8 (2020): e9392.
35. Rinaldi M., et al. “Galectin-1 circumvents lysolecithin-induced demyelination through the modulation of microglial polarization/phagocytosis and oligodendroglial differentiation”. Neurobiology of Disease 96 (2016): 127-143.
36. Wang X., et al. “Elevated galectin-3 levels in the serum of patients with Alzheimer's Disease”. American Journal of Alzheimer's Disease and Other Dementias 8 (2015): 729-732.
37. Tao CC., et al. “Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer's disease”. Cell Death and Differentiation1 (2020): 192-209.
38. Cancino GI., et al. “p63 Regulates adult neural precursor and newly born neuron survival to control hippocampal-dependent behavior”. Journal of Neuroscience 31 (2013): 12569-12585.
39. Kazi AS., et al. “Role of the PI3-kinase signaling pathway in trafficking of the surfactant protein A receptor P63 (CKAP4) on type II pneumocytes”. The American Journal of Physiology-Lung Cellular and Molecular Physiology 6 (2010): L794-L807.
40. Yanagita K., et al. “Cytoskeleton-associated protein 4 is a ovel serodiagnostic marker for lung cancer”. The American Journal of Pathology 6 (2018): 1328-1333.
41. Hultman K., et al. “The APOE ɛ4/ɛ4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients”. Journal of Cerebral Blood Flow and Metabolism 8 (2013): 1251-1258.
42. Beeri MS., et al. “Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers”. Neurology9 (2006): 1399-1404.
43. Kuo CL., et al. “APOEe4 genotype predicts severe COVID-19 in the UK Biobank community cohort”. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences (2020): glaa131.
44. Lim KH., et al. “Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer's disease”. Journal of Infection 3 (2020): e33-e34.
45. Susswein AJ., et al. “Nitric oxide and memory”. Neuroscientist 10 (2004): 153-162.
46. Alkeridy WA., et al. “A unique presentation of delirium in a patient with otherwise asymptomatic COVID-19”. Journal of the American Geriatrics Society (2020): 10.1111.

Citation

Citation: Mohammad Azizur Rahman., et al. “Neurobiochemical Crosstalk between COVID-19 and Alzheimer’s Disease". Acta Scientific Neurology 3.10 (2020): .

Copyright

Copyright: © 2020 Mohammad Azizur Rahman., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.